Literature DB >> 7869742

Cytarabine-induced pericarditis: a case report and review of the literature of the cardio-pulmonary complications of cytarabine therapy.

S Reykdal1, R Sham, P Kouides.   

Abstract

Pericarditis is a rare complication of chemotherapy. This report describes a patient who developed symptoms, signs, and electrocardiographic evidence of pericarditis following treatment with high dose cytarabine. The patient had no clinical or echocardiographic evidence of infection or leukemic involvement of the pericardium. Isolated pericarditis associated with high dose cytarabine has been rarely reported. This therapy is frequently used and, therefore, it seems prudent to alert physicians to this potential complication of cytarabine. The cardiopulmonary complications of cytarabine are also reviewed.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7869742     DOI: 10.1016/0145-2126(94)00123-r

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  13 in total

Review 1.  Cancer Treatment-Associated Pericardial Disease: Epidemiology, Clinical Presentation, Diagnosis, and Management.

Authors:  Chandra K Ala; Allan L Klein; Javid J Moslehi
Journal:  Curr Cardiol Rep       Date:  2019-11-25       Impact factor: 2.931

Review 2.  Cardio-oncology/onco-cardiology.

Authors:  Robert A Hong; Takeshi Iimura; Kenneth N Sumida; Robert M Eager
Journal:  Clin Cardiol       Date:  2010-12       Impact factor: 2.882

Review 3.  Uptake carriers and oncology drug safety.

Authors:  Jason A Sprowl; Alex Sparreboom
Journal:  Drug Metab Dispos       Date:  2013-12-30       Impact factor: 3.922

4.  Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.

Authors:  Juan Carlos Plana; Maurizio Galderisi; Ana Barac; Michael S Ewer; Bonnie Ky; Marielle Scherrer-Crosbie; Javier Ganame; Igal A Sebag; Deborah A Agler; Luigi P Badano; Jose Banchs; Daniela Cardinale; Joseph Carver; Manuel Cerqueira; Jeanne M DeCara; Thor Edvardsen; Scott D Flamm; Thomas Force; Brian P Griffin; Guy Jerusalem; Jennifer E Liu; Andreia Magalhães; Thomas Marwick; Liza Y Sanchez; Rosa Sicari; Hector R Villarraga; Patrizio Lancellotti
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2014-10       Impact factor: 6.875

5.  Post-transfusion breathlessness in a patient with acute myeloid leukaemia.

Authors:  Arjun Gupta; Kisan Parikh; Ambarish Pandey
Journal:  BMJ Case Rep       Date:  2015-06-23

Review 6.  Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention.

Authors:  V B Pai; M C Nahata
Journal:  Drug Saf       Date:  2000-04       Impact factor: 5.606

7.  Population-specific genetic variants important in susceptibility to cytarabine arabinoside cytotoxicity.

Authors:  Christine M Hartford; Shiwei Duan; Shannon M Delaney; Shuangli Mi; Emily O Kistner; Jatinder K Lamba; R Stephanie Huang; M Eileen Dolan
Journal:  Blood       Date:  2008-12-24       Impact factor: 22.113

8.  Pericarditis associated with cytarabine therapy for acute myelocytic leukemia: a case report.

Authors:  Xia Yang; Wei Liu; Allie Lyons; Zaiwei Song; Suodi Zhai; Kai Hu
Journal:  Eur J Clin Pharmacol       Date:  2017-10-27       Impact factor: 2.953

9.  Review of cardiotoxicity in pediatric cancer patients: during and after therapy.

Authors:  Joy M Fulbright
Journal:  Cardiol Res Pract       Date:  2011-05-23       Impact factor: 1.866

10.  Genome-wide local ancestry approach identifies genes and variants associated with chemotherapeutic susceptibility in African Americans.

Authors:  Heather E Wheeler; Lidija K Gorsic; Marleen Welsh; Amy L Stark; Eric R Gamazon; Nancy J Cox; M Eileen Dolan
Journal:  PLoS One       Date:  2011-07-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.